Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Dr. Max M. van Noesel, MD. PhD, MSc; – Princess Máxima Center, Utrecht, The Netherlands

We will develop a [89Zr]Dinutuximab for PET/CT to visualize and semiquantify GD2 expression in neuroblastoma for individual patients. Thereby providing insight in treatment effects and changes in GD2 expression. To achieve this we will:

1. Develop [89Zr]dinutuximab under GMP for clinical neuroblastoma imaging.

2. Dosimetry study for dose optimization in children, minimizing the radiation burden.

3. Perform a first-in-children [89Zr]dinutuximab imaging study, before and after therapy and in a relapse setting.